Loading...
01/11 16:22
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call summary reveals several positive elements such as increased revenue guidance and raised EPS projections. However, concerns arise from higher operating expenses, potential competition affecting VOXZOGO, and management's avoidance of specific details in the Q&A session. These mixed signals, combined with uncertainties about competition and market strategy, suggest a neutral sentiment with no clear strong positive or negative trend.
Total Revenue BioMarin reported an 11% year-over-year increase in total revenue for the year-to-date period, driven by strong performance in global enzyme therapies and Skeletal Conditions business units.
Enzyme Therapies Business Unit Revenue The Enzyme Therapies business unit achieved 8% year-to-date growth, although Q3 revenue was flat compared to Q3 2024 due to a higher volume of ALDURAZYME orders in the prior year.
VOXZOGO Revenue VOXZOGO revenue increased 24% year-to-date compared to 2024, with a projected full-year revenue of $900 million to $935 million, representing 25% growth at the midpoint of guidance.
PALYNZIQ Revenue PALYNZIQ revenue grew by more than 20% year-to-date, reflecting increased patient adherence and efficacy.
Operating Cash Flow Operating cash flow reached $369 million in Q3 and $728 million year-to-date, contributing to a total cash and investments balance of approximately $2 billion at the end of Q3.
Non-GAAP Operating Margin Non-GAAP operating margin guidance was updated to 26%-27%, reflecting strong revenue growth and operational execution despite higher R&D and SG&A expenses.
Diluted Earnings Per Share (Non-GAAP) Non-GAAP diluted earnings per share guidance was updated to $3.50-$3.60, incorporating the impact of a $221 million IPR&D charge related to the Inozyme Pharma acquisition.
VOXZOGO: Achieved 24% year-to-date revenue growth compared to 2024, reaffirmed 2025 revenue outlook of $900 million to $935 million. Expanded to 55 countries and is the standard of care for achondroplasia. Preparing for a second indication for hypochondroplasia with pivotal data expected in 2026.
BMN 333: Next-generation therapy for achondroplasia targeting superior efficacy compared to VOXZOGO. Phase II/III study initiation planned for the first half of 2026.
PALYNZIQ: Achieved over 20% year-to-date revenue growth. Pursuing approval for adolescents aged 12 to 17 in the U.S. and Europe by 2026.
Global Expansion of VOXZOGO: Now available in 55 countries, with 75% of revenue generated outside the U.S. Focused on increasing access and deeper penetration in existing markets.
Hypochondroplasia Market Preparation: Initiatives underway to improve early diagnosis and access globally. Potential launch in 2027 if data supports.
Revenue Growth: Achieved 11% year-to-date total revenue growth compared to 2024. Raised 2025 total revenue guidance to $3.15 billion.
Operational Cash Flow: Generated $728 million year-to-date, contributing to a $2 billion cash and investments balance.
Portfolio Optimization: Discontinuation of multiple research programs and decision to divest ROCTAVIAN to focus on strategic priorities.
Pipeline Development: Advancing multiple indications for VOXZOGO and BMN 333, along with other pipeline assets like BMN 351 and BMN 401.
Regulatory Hurdles: The company acknowledges that results may differ materially depending on the actions of regulatory authorities, which could impact product approvals and market access.
Strategic Execution Risks: The company has undertaken difficult decisions, including the discontinuation of multiple research programs and the divestment of ROCTAVIAN, which could impact its portfolio and strategic focus.
Market Competition: There is potential competition for VOXZOGO, which could impact revenue projections for 2027 and beyond.
Economic Uncertainties: The company faces uncertainties in revenue projections due to unknown variables over the next two years, which could affect financial performance.
Supply Chain and Operational Challenges: Quarter-to-quarter order timing dynamics and geographical dispersion of patients in the U.S. have created challenges in maintaining consistent revenue growth and patient uptake.
Financial Risks: The company incurred a $221 million charge for acquired in-process research and development, which significantly impacted operating margins and diluted earnings per share in Q3 2025.
Product-Specific Risks: The underdiagnosis of hypochondroplasia and barriers to genetic testing could limit the market potential for VOXZOGO's second indication.
Revenue Guidance: BioMarin raised the lower end of its full-year 2025 total revenue guidance to $3.15 billion, with the midpoint representing double-digit year-over-year growth. VOXZOGO revenue is expected to reach between $900 million and $935 million for 2025, with Q4 anticipated to be the highest revenue quarter of the year.
Profitability and Earnings: Full-year 2025 non-GAAP operating margin guidance has been updated to 26%-27%, and non-GAAP diluted earnings per share guidance is now between $3.50 and $3.60. The company expects continued strong operating cash flow and profitability growth.
VOXZOGO Expansion: VOXZOGO is expected to maintain strong growth, with global expansion and deeper market penetration. The company is preparing for a potential launch of VOXZOGO for hypochondroplasia in 2027, pending supportive data from a pivotal readout expected in the first half of 2026.
Pipeline Developments: BioMarin is advancing its skeletal conditions portfolio, including VOXZOGO for additional indications and BMN 333, a next-generation therapy for achondroplasia. Phase II/III studies for BMN 333 are expected to begin in the first half of 2026. The company is also pursuing approval of PALYNZIQ for adolescents aged 12-17 in 2026.
2027 Revenue Outlook: BioMarin provided a range of scenarios for 2027 revenue, excluding ROCTAVIAN, with the lower end aligning with current consensus estimates and the higher end potentially reaching $4 billion. However, no specific estimate or narrow range was provided due to uncertainties.
The selected topic was not discussed during the call.
The earnings call summary reveals several positive elements such as increased revenue guidance and raised EPS projections. However, concerns arise from higher operating expenses, potential competition affecting VOXZOGO, and management's avoidance of specific details in the Q&A session. These mixed signals, combined with uncertainties about competition and market strategy, suggest a neutral sentiment with no clear strong positive or negative trend.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
